RFX2

Across TCGA pan-cancer cohorts, RFX2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RFX2 data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RFX2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RFX2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

HNSC, LSCC, and UCEC are the cancer types where RFX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.381	0.936	.002	33	view →
LSCC	DFS	Quartile	All	0.176	0.892	.010	5	view →
UCEC	OS	Quartile	II,III,IV	0.524	1.000	.035	4	view →
CCRCC	DFS	Tertile	II,III,IV	0.803	0.469	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RFX2–HNSC (DFS)

Open the HNSC breakdown →